We explored how Saccharomyces cerevisiae affects patients with irritable bowel syndrome (IBS). In a study involving thirty participants, we administered 500 mg capsules of this yeast twice daily for four weeks. Weekly evaluations showed significant improvements in abdominal pain and general quality of life, with notable reductions in pain scores and enhancements in various aspects of daily living. This suggests Saccharomyces cerevisiae could be a valuable treatment option for alleviating IBS symptoms.
Read More
We investigated how saccharomyces cerevisiae affects gut motility in rats undergoing repeated water avoidance stress, simulating diarrhea-predominant irritable bowel syndrome.
The study revealed that treatment with saccharomyces cerevisiae significantly reduced excessive defecation and colonic hypermotility. We noted improvements in the contractile activity of colonic muscles, along with changes in immune responses and gut microbiota diversity.
Overall, saccharomyces cerevisiae showed promise for alleviating symptoms associated with IBS-D by addressing both gut motility and inflammation.
Read More
We conducted a study to assess the effectiveness of Saccharomyces cerevisiae CNCM I-3856 in treating irritable bowel syndrome (IBS). Using a randomized, placebo-controlled design, 100 newly diagnosed IBS patients received either the yeast or a placebo alongside standard treatment for 8 weeks.
We found significant reductions in abdominal pain and improved stool consistency in patients taking S. cerevisiae compared to the placebo group. All subgroups, including IBS-D, IBS-C, and IBS-M, showed notable benefits without serious adverse events.
Our findings suggest that S. cerevisiae can be a promising add-on therapy for IBS relief.
Read More
We explored the impact of the probiotic I-3856 on managing irritable bowel syndrome with predominant constipation (IBS-C) through a thorough eight-week randomized, double-blind study involving 456 participants.
The findings showed that 45.1% of those taking I-3856 reported significant relief from abdominal pain compared to 33.9% in the placebo group. While I-3856 improved quality of life scores, the study did not demonstrate significant changes in bowel movement frequency.
Overall, I-3856 shows promise in alleviating abdominal pain and enhancing quality of life for those suffering from IBS-C.
Read More
We examined the impact of CNCM I-3856 supplementation on irritable bowel syndrome (IBS) by analyzing data from two clinical trials involving 579 participants.
Our findings revealed notable improvements in abdominal pain and bloating among those taking CNCM I-3856 during the second month of treatment.
Participants in the active group showed better stool consistency and higher odds of symptom relief compared to those taking a placebo.
However, there were no significant differences at the end of the study, indicating mixed results on long-term benefits of this treatment for IBS.
Read More